Department of Biopharmaceutics and Clinical Pharmacy, School of Pharmacy, The University of Jordan, Amman, Jordan.
Faculty of Pharmacy, Department of Clinical Pharmacy and Therapeutics, Applied Science Private University, Amman, Jordan.
PLoS One. 2024 Jun 6;19(6):e0305011. doi: 10.1371/journal.pone.0305011. eCollection 2024.
Treatment-related problems (TRPs) interfere with the ability to attain the desired goals of treatment, adding cost to healthcare systems. Patients hospitalized with acute conditions are at particular risk to experience TRPs. Data investigating such burden in patients with acute exacerbation of COPD (AECOPD) is generally scarce with no studies ever conducted in Jordan. This study aimed to investigate and categorize TRPs among patients hospitalized with AECOPD in Jordan, and to estimate their cost savings and cost avoidance.
This was a retrospective population-based cohort study. Patients' cases of AECOPD admitted to the study site from Jan 2017 to Jul 2021 were identified from the electronic clinical database and screened for eligibility. TRPs were identified/categorized using AbuRuz tool and assessed for their severity. Cost saving was estimated by calculating all the extra costs. Cost avoidance was estimated according to Nesbit method.
A total of 1243 (mean±SD 3.1±1.5) and 503 (mean±SD 1.3±1.2) TRPs were identified during hospitalization and at discharge respectively, of which 49.4% and 66.7% were classified as "unnecessary drug therapy". In 54.5% of the cases, systemic corticosteroid was administered for a period longer than recommended. Most of the TRPs were of moderate severity. The total direct cost saving, and cost avoidance were estimated to be 15,745.7 USD and 340,455.5 USD respectively.
The prevalence and cost of TRPs among AECOPD patients is a concern requiring attention. The study results implicate integrating interventions such as embracing clinical pharmacists' role in the respiratory care units to optimize patients' management.
治疗相关问题 (TRPs) 会干扰实现治疗目标的能力,增加医疗保健系统的成本。患有急性疾病的住院患者尤其有经历 TRPs 的风险。一般来说,关于 COPD 急性加重 (AECOPD) 患者此类负担的数据很少,约旦从未进行过此类研究。本研究旨在调查和分类约旦 AECOPD 住院患者的 TRPs,并估计其节省和避免的成本。
这是一项回顾性基于人群的队列研究。从 2017 年 1 月至 2021 年 7 月,从电子临床数据库中确定了在研究地点因 AECOPD 入院的患者病例,并进行了筛选以确定其是否符合入选标准。使用 AbuRuz 工具识别/分类 TRPs,并评估其严重程度。通过计算所有额外成本来估计节省成本。根据 Nesbit 方法估计避免成本。
在住院期间和出院时分别确定了 1243 例(平均±SD 3.1±1.5)和 503 例(平均±SD 1.3±1.2)TRPs,其中 49.4%和 66.7%被归类为“不必要的药物治疗”。在 54.5%的情况下,给予了比推荐时间更长的全身皮质类固醇。大多数 TRPs 的严重程度为中度。直接总成本节省和避免成本分别估计为 15745.7 美元和 340455.5 美元。
AECOPD 患者中 TRPs 的发生率和成本令人担忧,需要引起关注。研究结果表明,需要整合干预措施,例如在呼吸护理单元中引入临床药师的角色,以优化患者的管理。